Go Pro
→ They didn't warn anyone in 1971. This time someone is warning you. (From Reagan Gold Group) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
$0.18
$0.18
$0.00
▼
$0.64
$208K5.962,326 shsN/A
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
$0.10
-0.1%		$0.15
$0.09
▼
$2.61
$653K2.074.36 million shs2.30 million shs
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
$0.01
$0.05
$0.00
▼
$0.33
$666K0.736,554 shs265 shs
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
$0.03
+3.3%		$0.07
$0.03
▼
$6.66
$483K0.09222,743 shs257,204 shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
0.00%0.00%0.00%0.00%+6,681.48%
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
-0.10%-20.71%-27.10%-56.80%-95.93%
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
0.00%0.00%-91.50%-91.50%-96.15%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
+3.33%-37.50%-53.24%-68.34%-99.07%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
$0.18
$0.18
$0.00
▼
$0.64
$208K5.962,326 shsN/A
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
$0.10
-0.1%		$0.15
$0.09
▼
$2.61
$653K2.074.36 million shs2.30 million shs
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
$0.01
$0.05
$0.00
▼
$0.33
$666K0.736,554 shs265 shs
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
$0.03
+3.3%		$0.07
$0.03
▼
$6.66
$483K0.09222,743 shs257,204 shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
0.00%0.00%0.00%0.00%+6,681.48%
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
-0.10%-20.71%-27.10%-56.80%-95.93%
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
0.00%0.00%-91.50%-91.50%-96.15%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
+3.33%-37.50%-53.24%-68.34%-99.07%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
0.00
N/AN/AN/A
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
1.00
SellN/AN/A
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
0.00
N/AN/AN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest AMPE, IMCC, PRPH, and NKGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/21/2026
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 8/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
N/AN/AN/AN/A$4.04 per shareN/A
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
$50.91M0.01N/AN/A($0.49) per share-0.21
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
N/AN/AN/AN/A($2.68) per shareN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
$5.06M0.10N/AN/A$2.46 per share0.01
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
-$8.63M-$11.01N/AN/AN/AN/AN/AN/AN/A
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
-$8.10M-$2.02N/AN/AN/A-39.62%-585.96%-58.32%N/A
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
-$82.94M-$1.68N/AN/AN/AN/AN/A-479.36%N/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
-$53.36M-$3.13N/AN/AN/A-825.01%-482.05%-88.90%8/21/2026 (Estimated)

Latest AMPE, IMCC, PRPH, and NKGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
N/A-$0.34N/A-$0.33N/A$5.34 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
N/AN/AN/AN/AN/A
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
N/AN/AN/AN/AN/A
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
N/AN/AN/AN/AN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
N/AN/AN/A
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
N/A
0.56
0.46
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
N/A
0.02
0.02
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
0.14
0.14
0.14

Institutional Ownership

CompanyInstitutional Ownership
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
5.73%
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
7.68%
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
76.17%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
9.45%

Insider Ownership

CompanyInsider Ownership
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
3.30%
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
N/A
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
10.36%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
9.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
201.14 million1.10 millionNo Data
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
3406.22 millionN/ANot Optionable
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
N/A130.60 million40.29 millionNot Optionable
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
13015.59 million5.44 millionNo Data

Recent News About These Companies

ProPhase Labs Delays Quarterly SEC Filing
August 14, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/prophase-labs-delays-quarterly-sec-filing?utm_source=marketbeat.com&utm_medium=referral
ProPhase Labs Inc.
July 16, 2026  |  marketwatch.comhttps://www.marketwatch.com/investing/stock/prph/financials/cash-flow
ProPhase Labs Announces Immediate Resignation of Board Member
June 25, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/PRPH/pressreleases/36984840/prophase-labs-announces-immediate-resignation-of-board-member/
ProPhase Labs Delays Quarterly Financial Filing
May 15, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/prophase-labs-delays-quarterly-financial-filing?utm_source=marketbeat.com&utm_medium=referral
ProPhase Labs Reports Year-End 2025 Results, Highlights Accelerating Settlement Activity and Investment-Ready Crown Medical Collections Platform
April 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/15/3274530/0/en/prophase-labs-reports-year-end-2025-results-highlights-accelerating-settlement-activity-and-investment-ready-crown-medical-collections-platform.html
ProPhase Labs Provides Business Update Highlighting Advancing Crown Medical Collections Activity
March 18, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/prophase-labs-provides-business-highlighting-120000129.html
ProPhase Labs Explores Strategic Options for BE-Smart Test
February 13, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/prophase-labs-explores-strategic-options-for-be-smart-test?utm_source=marketbeat.com&utm_medium=referral
ProPhase Labs, Inc.: ProPhase Labs Initiates Potential Sale or Strategic Partnership of BE-Smart and Advances Crown Medical Collections Initiative
February 3, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-02/67599969-prophase-labs-inc-prophase-labs-initiates-potential-sale-or-strategic-partnership-of-be-smart-and-advances-crown-medical-collections-initiative-399.htm
ProPhase Labs Initiates Potential Sale or Strategic Partnership of BE-Smart™ and Advances Crown Medical Collections Initiative
February 3, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/prophase-labs-initiates-potential-sale-120000291.html
ProPhase Labs initiates potential sale or strategic partnership of BE-Smart
February 3, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4546120-prophase-labs-initiates-potential-sale-or-strategic-partnership-of-be-smart
Join ProPhase Labs’ Exclusive Live Investor Webinar and Q&A Session on February 3rd
February 2, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/join-prophase-labs-exclusive-live-investor-webinar-and-q-a-session-on-february-3rd-1035773219
ProPhase Labs Provides Crown Medical Collections Update; 250+ Insurance Payors Engaged, Approximately 50 Matters in Advanced Settlement Posture
January 26, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/prophase-labs-provides-crown-medical-collections-update-250-insurance-payors-engaged-approximately-50-matters-in-advanced-settlement-posture-1035745250
ProPhase Labs Secures Flexible $10 Million Equity Facility
January 23, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/prophase-labs-secures-flexible-10-million-equity-facility?utm_source=marketbeat.com&utm_medium=referral
ProPhase Labs Uplists from Pink Sheets to OTC Market
January 22, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/prophase-labs-uplists-from-pink-sheets-to-otc-market-1035736260
ProPhase Labs Provides Update on Convertible Debt Conversions, Capital Structure, and Underlying Asset Value
January 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/01/05/3212517/0/en/prophase-labs-provides-update-on-convertible-debt-conversions-capital-structure-and-underlying-asset-value.html
ProPhase Labs faces NASDAQ delisting, plans appeal, OTC move
January 3, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/prophase-labs-faces-nasdaq-delisting-plans-appeal-otc-move/ar-AA1TtNWj
ProPhase Labs signs non-binding LOI for proposed reverse merger with ABL
December 19, 2025  |  msn.comhttps://www.msn.com/en-us/money/mergers-and-acquisitions/prophase-labs-signs-non-binding-loi-for-proposed-reverse-merger-with-abl/ar-AA1SGkg8
ABL Diagnostics Informs the Market of a Non‑Binding Letter of Intent Between ABL S.A. and ProPhase Labs (Nasdaq: PRPH) for a Proposed Reverse Merger
December 19, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/abl-diagnostics-informs-market-non-070000608.html
ProPhase Labs stock soars after announcing reverse merger with ABL
December 19, 2025  |  au.investing.comhttps://au.investing.com/news/stock-market-news/prophase-labs-stock-soars-after-announcing-reverse-merger-with-abl-93CH-4179598
ProPhase Labs Signs Non-Binding LOI for Proposed Reverse Merger with Advanced Biological Laboratories
December 19, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/12/19/3208405/0/en/prophase-labs-signs-non-binding-loi-for-proposed-reverse-merger-with-advanced-biological-laboratories.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ampio Pharmaceuticals stock logo

Ampio Pharmaceuticals NYSE:AMPE

$0.18 0.00 (0.00%)
As of 08/17/2026

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.

IM Cannabis stock logo

IM Cannabis NASDAQ:IMCC

$0.10 0.00 (-0.10%)
Closing price 08/18/2026 04:00 PM Eastern
Extended Trading
$0.10 -0.01 (-5.24%)
As of 08/18/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.

NKGen Biotech stock logo

NKGen Biotech NYSE:NKGN

$0.0051 0.00 (0.00%)
As of 08/17/2026 09:42 AM Eastern

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.

ProPhase Labs stock logo

ProPhase Labs NASDAQ:PRPH

$0.03 +0.00 (+3.33%)
As of 08/18/2026 01:54 PM Eastern

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas